Sangart Adds $50M to Their Total Equity Funding

Sangart Inc. will be looking at further clinical development as they receive their Series G equity funding worth $50 million from Leucadia National Corporation. The latter is already an existing investor.

Sangart Inc. has now raised over $280 millionĀ in financing.

The company’s CEO Brian O’Callaghan happily shares more information about this recent funding in this e-interview with Lead411:

Read More

Sangart Secures Series G Financing

Sangart has recently made known some great news. The company has acquired more than $50 million in Series G equity funding, giving them a total funding to date of over $230 million.

The most recent round was led by Leucadia National Corporation.

Their CEO Brian O’Callaghan shares some more information about the company in this recent e-interview with Lead411:

Read More